ERBB2 and non-small cell lung carcinoma: The combination of trastuzumab and pertuzumab showed a modest ORR of 11% in heavily pre-treated patients with HER2-mutant or amplified NSCLC, particularly in those harbouring HER2 exon 20 mutations [46].